Pharmaceutical Executive

In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases, EMD Serono’s agreement with the Trump administration to expand access to in vitro fertilization therapies, and how the obesity treatment market is evolving after GLP-1 dominance.

In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.

In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.

In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.

Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.

In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.

In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and market implications of the Most Favored Nation drug pricing proposal, and the FDA’s approval of Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma.

In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCSA compliance is only the beginning of pharma supply chain modernization, and the agency’s approval of Jascayd for idiopathic pulmonary fibrosis.

In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch of its new direct-to-consumer platform AmgenNow, and AstraZeneca’s multi-target research partnership with Algen.

In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program Nuz-001, the agency’s export ban on Sun Pharma’s Halol facility, and new insights on how small biotechs can better navigate regulatory and market complexities.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, we cover lessons from FDA complete response letters shaping CMC strategy in cell and gene therapy, Takeda’s decision to discontinue its cell therapy research programs, and the CDC’s latest update to COVID-19 vaccination rec...

In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.

Stay informed on key pharmaceutical news, including tariff updates, FDA shutdown risks, and insights from recent cell and gene therapy reviews.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy for primary humoral immunodeficiency, and Eli Lilly’s decision to halt development of a muscle-preserving weight-loss therapy.

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to harmonize its global stock exchange listings, and reports that President Trump will announce a government-run direct-to-patient drug purchasing website.

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of Regeneron’s Evkeeza for children with homozygous familial hypercholesterolemia.

In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the FDA’s approval of Eli Lilly’s Inluriyo for ESR1-mutated metastatic breast cancer, and President Trump’s call for steep tariffs on branded pharmaceuticals

In today’s Pharmaceutical Executive Daily, we cover Glenmark’s billion-dollar exclusive licensing deal with Hengrui, Harmony Biosciences’ trial setback for Zygel, and the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations.

In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to Scholar Rock for its spinal muscular atrophy treatment, and a closer look at the state of evidence linking Tylenol use and autism risk.

In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete response letter to Otsuka and Lundbeck’s sNDA for Rexulti, and the medical community’s response to former President Trump’s claims linking Tylenol use to autism risk.

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.